A newly published cache of CRLs includes six novel oncology drugs.
ApexOnco Front Page
Recent articles
The deal for ISB 2001 is worth $700m up front.
The group goes after a KRAS-related target on which Boehringer recently gave up.
Conferences ramp up, and ASH abstracts near.
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.